Comparative study of drug release in vitro of polylactic acid/polyglycolic acid coated triple anti-tuberculosis drug-loading artificial bone

doi:10.3969/j.issn.2095-4344.2017.06.016

Abstract

Abstract:

BACKGROUND: Calcium sulfate/polyamino acid artificial bone material carrying triple anti-tuberculosis drugs (isoniazide, rifampicin, pyrazinamide) has good release characteristics and antibacterial activity, but its shortcomings also exist for the phenomenon of burst, due to a faster degradation of calcium sulfate.
OBJECTIVE: To observe the effect of polylactic acid/polyglycolic acid copolymer (PLGA) coating on drug release behavior in vitro of triple anti-tuberculosis drugs containing calcium sulfate/polyamino acid bone.
METHODS: According to the selected optimum recipe, we prepared drug-loading artificial bones and non-drug-loading artificial bones in a dark place. After infiltrating in PLGA, drying and sterilizing, we soaked them in simulated body fluid for drug release experiments. Through high performance liquid chromatography method, the concentrations of isoniazide, rifampicin, pyrazinamide released at different times were observed.
RESULTS AND CONCLUSION: For triple anti-tuberculosis drugs drug artificial bone with no PLGA coating, the drug release of isoniazide accounted for 91.75% of the total drug loading capacity at 7 weeks; the drug releases of rifampicin and pyrazinamide respectively accounted for 88.34% and 49.35% of their own total drug loading capacity at 8 weeks. For triple anti-tuberculosis drug artificial bone with PLGA coating, the drug release of isoniazide accounted for 43.51% of the total drug loading capacity at 17 weeks; the drug releases of rifampicin and pyrazinamide respectively accounted for 15.92% and 48.42% of their own total drug loading capacity at 16 weeks. For blank control group, the drug peak was not noticed in effective detection period. These findings indicate that PLGA coated triple anti-tuberculosis drug-loading calcium sulfate/polyamino acid artificial bone can control drug release, increase the release period and maintain a high level of drug concentration in local lesion for a long time, so as to give full play to the anti-tuberculosis function of triple anti-tuberculosis drug loading artificial bone.

中国组织工程研究杂志出版内容重点：生物材料；骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性；组织工程

Key words: Tissue Engineering, Biocompatible Materials, Calcium Sulfate

CLC Number:

R318

Wang Qian, Liu Hai-tao, Shi Jian-dang, Wang Zi-li, Geng Guang-qi, Niu Ning-kui, Wang Jie, Yan Jun-fa. Comparative study of drug release in vitro of polylactic acid/polyglycolic acid coated triple anti-tuberculosis drug-loading artificial bone[J]. Chinese Journal of Tissue Engineering Research, 2017, 21(6): 911-916.

Figures/Tables 7

References

[1]Diacon AH, Donald PR. The early bactericidal activity of antituberculosis drugs. Exp Rev Anti Infect Ther. 2014;12(2): 223-237.

[2]Ge Z, Wang Z, Wei M. Measurement of the concentration of three antituberculosis drugs in the focus of spinal tuberculosis. Eur Spine J. 2008;17(11):1482-1487.

[3]龙娜,吕竹芬.微球缓释系统的突释现象及其影响因素[J].中国药师,2010,13(3):421-423.

[4]德向研,施建党,王自立,等.载三联抗结核药硫酸钙/氨基酸聚合物人工骨体内缓释实验研究[J].中国脊柱脊髓杂志,2013,23(6): 531-536.

[5]刘海涛,王自立,施建党,等.人工骨载三联抗结核药物含量对其抗机械压缩强度的影响[J].宁夏医科大学学报, 2013,35(7): 759-762.

[6]刘海涛,施建党,王骞,等.载三联抗结核药物硫酸钙/聚氨基酸人工材料体外缓释性能的观察[J].中国脊柱脊髓杂志, 2015,25(3): 239-244.

[7]Chen J, Gao J, Yin H, et al. Size-controlled preparation of α-calcium sulphate hemihydrate starting from calcium sulphate dihydrate in the presence of modifiers and the dissolution rate in simulated body fluid. Mater Sci Eng C Mater Biol Appl. 2013;33(6):3256-3262.

[8]Hirota K, Hasegawa T, Nakajima T, et al. Delivery of rifampicin-PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis. J Control Release. 2010;142(3):339-346.

[9]赵锡江,齐新生,董寅生.rhBMP-2/PLGA缓释支架的制备及对MSCs细胞成骨活性的体外研究[J].国际生物医学工程杂志, 2010,33(3):147-151.

[10]Ratier A, Freche M, Lacout JL, et al. Behaviour of an injectable calcium phosphate cement with added tetracycline. Int J Pharm. 2004;274(1-2):261-268.

[11]Joosten U, Joist A, Frebel T, et al. Evaluation of an in situ setting injectable calcium phosphate as a new carrier materials for gentamicin in the treatment of chronic osteomyelitis: studies in vitro and in vivo. Biomaterials. 2004; 25(18):4287-4295.

[12]Krasko MY, Golenser J, Nyska A, et al. Gentamicin extended release from an injectable polymericim plant. J Control Release. 2007;117(1):90-96.

[13]曹丰亮,席延伟,唐琳,等.姜黄素肺靶向明胶微球的制备及性质研究[J].中药材,2009,3(32):423-426.

[14]黄莹莹,齐民,杨大智,等.冠脉支架表面PLGA涂层制备及其血液相容性研究[J].功能材料,2006,37(3):411-414.

[15]张峻山,王自立,施建党,等.复合三联抗结核药人工缓释材料体外抗结核性能[J].脊柱外科杂志,2014,12(6):380-384.

[16]Geng G, Wang Q, Shi J, et al. Establishment of a new zealand rabbit model of spinal tuberculosis. J Spinal Disord Tech. 2015; 28(3):E140-E145.

[17]刘海涛,施建党,王骞,等.硫酸钙/聚氨基酸复合三联抗结核药人工缓释材料的制备及物理性能测定[J].中国矫形外科杂志,2015, 23(21):1984-1988.

[18]张立群,李华,巩维进.结核病的化学治疗[J].中国临床医生,2009, 37(21):165-166.

[19]周林.抗结核药物研究进展[J].中国临床医生,2013,41(3):14-17.

[20]李群力,蒋晓萌,施存元.高效液相色谱法测定复方利福平片中利福平、异烟肼及吡嗪酰胺的含量[J].中国抗生素杂志,2002,27(9): 570-571.

[21]Guo H, Wei J, Liu CS. Development of a degradable cement of calcium phosphate and calcium sulfate composite for bone reconstruction. Biomed Mater. 2006;1(4):193-197.

[22]Urban RM, Turner TM, Hall DJ, et al. Increased bone formation using calcium sulfate-calcium phosphate composite graft. Clin Orthop Relat Res. 2008;459:110-117.

[23]Civinini R, De B, Carulli C, et al. The use of an injectable calcium sulphate/calcium phosphate bioceramic in the treatment of osteonecrosis of the femoral head. Int Orthop. 2012;36(8):1583-1588.

[24]张卓,孙宇航,耿广起,等.载三联抗痨药硫酸钙/聚氨基酸人工骨植入脊柱结核病灶内:植骨界面的组织学改变[J].中国组织工程研究,2016,20(47):7027-7033.

[25]应吕方,贾叙锋,程尹,等.硫酸钙人工骨复合培养骨髓间充质干细胞对骨诱导脊柱融合的影响[J].中国组织工程研究,2016,20(43): 6396-6402.